Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction
Inflammation expert opinionsSep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.
Video navigation menu
- CANTOS was one of the highlights of ESC 2017 00:22
- CANTOS shows that inflammation plays a causal role in the atherogenic process 01:11
- Education of cardiologists is essential to familiarize with this new treatment option 01:46
- Patient selection is crucial and has to be discussed 02:30
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Wolfgang Koenig, MD, PhD, FRCP, FACC, FAHA, FESC is a Professor of Medicine/Cardiology at the University of Ulm Medical School, Ulm, Germany.
Funding to produce expert opinion was provided by an unrestricted educational grant from Novartis.